Sichuan Biokin Pharmaceutical Co., Ltd.SSE: 688506

Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in Combination with Radiotherapy for the Treatment of Locally Advanced Unresectable Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

On 6ix: 6ix.com/news/sichuan-biokin-pharmaceutical-co-ltdannouncement-on-voluntary-disclosure-of-receipt-of-the-clinical-trial-approval-notice-for-yizekang-izalontamab-brengitecan-bl-b01d1iza-bren-in-combination-with-radiotherapy-for-the-treatment-of-locally-advanced-unresectable-head-and-neck-squamous-cell-carcinoma-and-other-solid-tumors

Release

Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in Combination with Radiotherapy for the Treatment of Locally Advanced Unresectable Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix

Earlier from Sichuan Biokin Pharmaceutical

Later from Sichuan Biokin Pharmaceutical

All Sichuan Biokin Pharmaceutical news releases